(Q28344992)

English

Evidence for a schedule-dependent deleterious interaction between paclitaxel, vinblastine and cisplatin (PVC) in the treatment of advanced transitional cell carcinoma

scientific article

In more languages

Statements

scholarly article

0 references

Evidence for a schedule-dependent deleterious interaction between paclitaxel, vinblastine and cisplatin (PVC) in the treatment of advanced transitional cell carcinoma (English)

0 references

transitional cell carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

C Mulatero

1

0 references

B R McClaren

2

0 references

M Mason

3

0 references

R T Oliver

4

0 references

C J Gallagher

5

0 references

language of work or name

0 references

publication date

December 2000

0 references

British Journal of Cancer

0 references

83

0 references

1612-6

0 references

12

0 references

Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363438

29 September 2017

Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363438

29 September 2017

Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363438

29 September 2017

Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363438

29 September 2017

Methotrexate: an active drug in bladder cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363438

29 September 2017

Chemotherapy of urothelial tract tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363438

29 September 2017

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363438

29 September 2017

Cis-dichlorodiammineplatinum(II) in advanced bladder cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363438

29 September 2017

Assessment of response to therapy in advanced breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363438

29 September 2017

Phase II evaluation of cis-dichlorodiammineplatinum(II) in lymphomas: a Southwest Oncology Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363438

29 September 2017

Adriamycin in advanced urinary tract cancer.Experience in 42 patients and review of the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363438

29 September 2017

Methotrexate in the Treatment of Metastatic and Recurrent Primary Transitional Cell Carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363438

2 June 2018

Cancer statistics, 1997.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363438

27 November 2018

Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363438

27 November 2018

Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/11104554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Accelerated cisplatin-based chemotherapy for advanced bladder cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/11104554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combinations of paclitaxel and vinblastine and their effects on tubulin polymerization and cellular cytotoxicity: characterization of a synergistic schedule

1 reference

https://pubmed.ncbi.nlm.nih.gov/11104554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of advanced bladder cancer with cis-diamminedichloroplatinum (II NSC 119875): a pilot study

1 reference

https://pubmed.ncbi.nlm.nih.gov/11104554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cis-diamminedichloroplatinum as a therapeutic agent in metastatic transitional cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/11104554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cis-diamminedichloride platinum II in the treatment of advanced bladder cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/11104554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase 2 study of Cis-platinum in patients with recurrent bladder carcinoma. The London and Oxford Co-operative Urological Cancer Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/11104554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of vinblastine sulfate for metastatic urothelial tract tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/11104554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium

1 reference

https://pubmed.ncbi.nlm.nih.gov/11104554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine

1 reference

https://pubmed.ncbi.nlm.nih.gov/11104554

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1054/BJOC.2000.1480

0 references

Dimensions Publication ID

0 references

release_ozlehdjhzbfxznng5nzhmuxasq

0 references

0 references

0 references

ResearchGate publication ID

0 references

Springer Nature article ID

10.1054/bjoc.2000.1480

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28344992&oldid=1834283415"